Naturally restoring the heart valve

Xeltis is a clinical-stage medical device company developing the first heart valves enabling the body’s natural restoration of heart valve function.

Xeltis’ RestoreX platform is the world’s first polymer-based technology designed to enable restorative heart valve therapy through a process called Endogenous Tissue Restoration (ETR).

Potentially addressing 100,000s
patients / year
The RestoreX innovative technology platform comprises a number of potential applications to cardiovascular conditions and patient populations.

Xeltis closed a $33 Million Series B Financing ($30 million in 2014, extended by $3 million in 2015) supporting clinical evaluation and market development for its innovative technology.

“Xeltis has the potential to transform the way heart valve disease is treated in the future.”

- Michel Darnaud, Chairman of the Board of Xeltis

Xeltis is accelerating progression

2006
  • Swiss Xeltis founded as Univeristy of Zurich spin-off
2012
  • Xeltis merges with Dutch Qtis/e, becoming today’s Xeltis
2013
  • Feasibility clinical trials start (patch and conduit)
2014
  • Series B financing round closed
2015
  • Executive team expands, team reaches 30+
  • Series B financing extended
2016
  • 2-year clinical data on bioabsorbable cardiovascular technology presented at EACTS
  • Pulmonary valve, first commercial product, enters clinical trial phase
  • International Clinical and Scientific Advisory Boards set-up
  • Aortic valve enters preclinical trial phase
2017
  • US FDA approved Investigational Device Exemption (IDE) for PV Early Feasibility Study (EFS)
  • 6-month preclinical data on Aortic Valve presented at EuroPCR

Xeltis has been recognized as a breakthrough medtech start-up

Awarded

Gold Testing & Treatment Options at 2017 Edison Awards

Included

Fierce 15 list by Fierce Medical Devices 2015

Nominated

Out-of-the-box technology at PCR 2015

Awarded

Biovision Next Gem Award 2013

Recognized

Promising Start-up by IMD Business School

Selected

Top-25 Tech-tour Medtech Summit 2012

XELTIS CEO, Laurent Grandidier
  • Included in the 2016 100 Power List by Medicine Maker
  • Nominated 2015 Best CEO in the Medical Device Industry by magazine European CEO